Gilead Sciences, Inc. (NASDAQ:GILD) was downgraded by research analysts at Vetr from a “strong-buy” rating to a “buy” rating in a note issued to investors on Monday. They currently have a $82.15 price target on the biopharmaceutical company’s stock. Vetr‘s price objective would indicate a potential upside of 11.33% from the stock’s previous close.

Several other equities analysts have also commented on the company. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price objective for the company in a research report on Tuesday, May 2nd. BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Credit Suisse Group reissued an “outperform” rating and set a $79.00 price objective on shares of Gilead Sciences in a research report on Monday, May 15th. Gabelli reissued a “buy” rating and set a $85.00 price objective on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Finally, J P Morgan Chase & Co reissued an “overweight” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 4th. Eleven equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. Gilead Sciences has an average rating of “Buy” and an average price target of $80.58.

Shares of Gilead Sciences (NASDAQ:GILD) opened at 73.79 on Monday. The company’s 50 day moving average is $72.97 and its 200-day moving average is $68.86. Gilead Sciences has a one year low of $63.76 and a one year high of $82.07. The firm has a market capitalization of $96.36 billion, a price-to-earnings ratio of 8.01 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.08 earnings per share. Equities analysts expect that Gilead Sciences will post $8.74 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Vetr Inc. Lowers Gilead Sciences, Inc. (GILD) to Buy” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://theolympiareport.com/2017/08/28/vetr-inc-lowers-gilead-sciences-inc-gild-to-buy.html.

In related news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 206,666 shares of company stock valued at $15,223,184. 1.30% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in GILD. Paradigm Financial Advisors LLC increased its position in shares of Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 26 shares during the period. RNC Capital Management LLC increased its position in shares of Gilead Sciences by 1.4% in the second quarter. RNC Capital Management LLC now owns 83,702 shares of the biopharmaceutical company’s stock worth $5,924,000 after buying an additional 1,185 shares during the period. Sentry Investment Management LLC increased its position in shares of Gilead Sciences by 1.2% in the second quarter. Sentry Investment Management LLC now owns 140,100 shares of the biopharmaceutical company’s stock worth $9,916,000 after buying an additional 1,606 shares during the period. WFG Advisors LP increased its position in shares of Gilead Sciences by 42.5% in the second quarter. WFG Advisors LP now owns 3,197 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 953 shares during the period. Finally, Toronto Dominion Bank increased its position in shares of Gilead Sciences by 19.0% in the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock worth $33,445,000 after buying an additional 75,364 shares during the period. Institutional investors own 74.02% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.